Search results
Q1 2024 EOG Resources Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 2 days agoAnn is up next to provide an update on our forecast and 3-year scenario. Here's Ann. Ann D. Janssen Thanks, Ezra. Given the recent strength in commodity prices, we have updated ...
Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024
WJTV Jackson· 3 days agoJohnson & Johnson today announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual ...
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk...
WTNH-TV New Haven· 2 days agoJohnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study...
Microbiome researchers challenge the state of the art in colon cancer biomarker discovery
Medical Xpress· 6 days agoFor the first time, researchers from VIB-KU Leuven, UZ Leuven, Janssen Pharmaceutica and multiple...
Leukemia Therapeutics Market Expected to Grow at USD 13491.42 Million by 2030: SNS Insider
Digital Journal· 2 days agoThe global leukemia therapeutics market has witnessed significant growth in recent years, driven by...
Earnings call: Nanobiotix reports progress in solid tumor treatment
Investing.com· 7 days agoThe company reported promising Phase 1 trial results in head and neck and pancreatic cancers, and...
Addex Therapeutics Shares Plunge Premarket on Epilepsy Study Failure
Morningstar· 7 days agoU.S.-listed shares Addex Therapeutics plunged nearly 60% in premarket trading Monday after the clinical-stage biopharmaceutical company reported the failure of a mid-stage study of a proposed ...
Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies - Cell...
Nature· 4 days agoForkhead box protein M1 (FOXM1) is often overexpressed in human cancers and strongly associated with therapy resistance and less good patient survival. The chemotherapy options for patients ...
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study - Addex Therapeutics (NASDAQ:ADXN)
Benzinga· 7 days agoAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
Glecirasib Shows Promising Efficacy in KRAS-Mutated NSCLC
MedPage Today· 5 days agoTrend towards better response rate, PFS compared with approved KRAS inhibitors
